# EDGAR Filing Document

**Accession Number:** 0000832489
**File Stem:** 0001437749-26-001113
**Filing Date:** 2026-1
**Character Count:** 9355
**Document Hash:** 092bae08956e6a7d8885f4bef3d7807e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001437749-26-001113.hdr.sgml**: 20260112

**ACCESSION NUMBER**: 0001437749-26-001113

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 17

**CONFORMED PERIOD OF REPORT**: 20260109

**ITEM INFORMATION**: Material Modifications to Rights of Security Holders

**ITEM INFORMATION**: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260112

**DATE AS OF CHANGE**: 20260112

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** GeoVax Labs, Inc.
- **CENTRAL INDEX KEY:** 0000832489
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 870455038
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39563
- **FILM NUMBER:** 26527180

**BUSINESS ADDRESS:**
- **STREET 1:** 1955 LAKE PARK DRIVE
- **STREET 2:** SUITE 300
- **CITY:** SMYRNA
- **STATE:** GA
- **BUSINESS PHONE:** 678-384-7220

**MAIL ADDRESS:**
- **STREET 1:** 1955 LAKE PARK DRIVE
- **STREET 2:** SUITE 300
- **CITY:** SMYRNA
- **STATE:** GA

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Geovax Labs, Inc.
- **DATE OF NAME CHANGE:** 20061002

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** DAUPHIN TECHNOLOGY INC
- **DATE OF NAME CHANGE:** 19940826

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SUCCESSO INC
- **DATE OF NAME CHANGE:** 19910410

?xml version='1.0' encoding='ASCII'? govx20260109_8k.htm

--12-31

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

------

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

**Date of report (Date of earliest event reported): January 9, 2026**

------

**GEOVAX LABS, INC.**

**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-39563** | **87-0455038** |
| **(State or other jurisdiction of**<br> **incorporation or organization)** | **(Commission File No.)** | **(IRS Employee Identification No.)** |

---

**1955 Lake Park Drive, Suite 300**

**Smyrna, Georgia 30080**

**(Address of principal executive offices) (Zip code)**

&nbsp;&nbsp;&nbsp;&nbsp;**(678) 384-7220**

**(Registrant**'**s telephone number, including area code)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions.

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13(e)-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading<br> Symbol(s) | Name of each exchange on which registered |
| Common Stock, par value $0.001 per share | GOVX | The Nasdaq Capital Market |

---

Indicate by check mark whether the Registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial reporting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 3.03** | **Material Modification to Rights of Security Holders** |

---

To the extent required by Item 3.03 of Form 8-K, information regarding the Reverse Stock Split (as defined in Item 5.03 below) contained in Item 5.03 of this Current Report on Form 8-K is incorporated by reference herein.

---

| | |
|:---|:---|
| **Item 5.03**  | **Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year** |

---

On January 9, 2026, GeoVax Labs, Inc. (the "Company" or "we") filed a Certificate of Amendment to our Certificate of Incorporation effecting a 1-for-25 reverse stock split pursuant to which each twenty-five (25) shares of the Company's Common Stock, par value $0.001 per share ("Old Common Stock"), issued and outstanding immediately prior to the filing automatically and without any action on the part of the respective holders thereof, was combined and reclassified into one (1) share of Common Stock, par value $0.001 per share (the "New Common Stock") (and such combination and conversion, the "Reverse Stock Split"). No fractional shares of New Common Stock were issued in connection with the Reverse Stock Split. Immediately after the Reverse Stock Split, each stockholder's percentage ownership interest in the Company and proportional voting power remains unchanged, except for minor changes and adjustments resulting from the rounding up of any fractional shares to the next whole number of shares. The rights and privileges of the holders of shares of Common Stock are substantially unaffected by the Reverse Stock Split.

The foregoing summary is qualified in its entirety by reference to the text of the Certificate of Amendment to the Certificate of Incorporation, a copy of which is filed herewith as Exhibit 3.1.

**Item 9.01 Financial Statements and Exhibits.**

(d) <u>Exhibits</u>.

---

| | |
|:---|:---|
| Exhibit Number | Description |
| 3.1 | [Certificate of Amendment to the Certificate of Incorporation of GeoVax Labs, Inc. filed January 9, 2026](ex_906010.htm) |
| 4.1 | [Form of Stock Certificate to be issued after January 9, 2026 to represent the Company's Common Stock, par value $0.001 per share](ex_906011.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: January 12, 2026

---

| | |
|:---|:---|
| GEOVAX LABS, INC. | GEOVAX LABS, INC. |
| By: | */s/ Mark W. Reynolds* |
|  | Mark W. Reynolds |
|  | Chief Financial Officer |

---

## Exhibit 3.1

**Exhibit 3.1**

**CERTIFICATE OF AMENDMENT<br> TO THE CERTIFICATE OF INCORPORATION<br> OF<br> GEOVAX LABS, INC.**

GeoVax Labs, Inc. (the "Corporation"), does hereby certify that the Corporation's Certificate of Incorporation originally filed with the Delaware Secretary of State on June 17, 2008, and as restated on April 12, 2024, is hereby amended pursuant to Section 242 of the General Corporation Law of the State of Delaware.

The Corporation does hereby further certify that this Certificate of Amendment was duly adopted by the Corporation's Board of Directors and by the stockholders of the Corporation in accordance with the applicable provisions of Section 242 of the General Corporation Law of the State of Delaware.

The Certificate of Incorporation of the Corporation, as amended, is amended as follows:

The first paragraph of Article IV of the Certificate of Incorporation, as amended, shall be deleted in its entirety and replaced with the following:

"The total number of shares of all classes of stock which the Corporation shall have the authority to issue is 160,000,000 shares, which are divided into two classes consisting of: (a) 150,000,000 shares of Common Stock, par value $0.001 per share, and (b) 10,000,000 shares of Preferred Stock, par value $0.01 per share.

Upon the effectiveness of this Certificate of Amendment of the Certificate of Incorporation (the "Effective Time"), each twenty-five (25) shares of the Corporation's Common Stock, par value $0.001 per share ("Old Common Stock"), issued and outstanding immediately prior to the Effective Time will automatically and without any action on the part of the respective holders thereof, be combined and reclassified into one (1) share of Common Stock, par value $0.001 per share (the "New Common Stock") (and such combination and conversion, the "Reverse Stock Split"). Notwithstanding the immediately preceding sentence, no fractional shares of New Common Stock shall be issued to the holders of record of Old Common Stock in connection with the Reverse Stock Split. Stockholders of record who would otherwise hold fractional shares because the number of shares of common stock they hold before the reverse stock split is not evenly divisible by the reverse stock split ratio will be rounded up to the nearest whole share."

The remainder of the Certificate of Incorporation shall remain unchanged and in full force and effect.

This Certificate of Amendment shall be effective as of 5:00 p.m. Eastern Time on January 9, 2026.

IN WITNESS WHEREOF, the Corporation has caused this Certificate of Amendment to be signed on January 9, 2026.

GEOVAX LABS, INC.<br>*<u>/s/ David A. Dodd</u>*<u> </u><br> David A. Dodd<br> President and Chief Executive Officer<br>

## Exhibit 4.1

**Exhibit 4.1**

![ex01.jpg](ex01.jpg)

------

![ex2.jpg](ex2.jpg)